newsfilter
← Latest News
Business Wire·

Exscientia Initiates Clinical Study to Further Evaluate Functional Precision Medicine Platform in Cancer Patients

Multicentre EXCYTE-2 study to evaluate precision medicine platform in patients with acute myeloid leukaemia Supports ongoing development of LSD1 inhibitor (EXS74539) currently in preclinical development Exscientia